Clinical Evaluation of FLACS (Femtosecond Laser Assisted Cataract Surgery) With Combination of LenSx® and Centurion®
Phase: NA
Conditions: Cataract
Sponsor: Alcon Research

 
 
 
 
 
 
 
Clinical Evaluation of FLACS (Femtosecond Laser Assisted 
Cataract Surgery) with Combination of LenSx and Centurion 
 
 
 
 
Clinical Study Protocol 
 
 
 
 
 
 
 
 
 
Alcon Japan Ltd. 
1-23-1, Toranomon, Minato-ku, Tokyo 
 
 
 
Protocol number: CTB258-P001 
Version No.2: May 18 2018 
 
 

Protocol No.: CTB258-P001 
1/33 
1 
SUMMARY 
Protocol number 
CTB258-P001 
Objectives 
To demonstrate less Cumulative Dissipated Energy (CDE), lower 
endothelial cell less and lower average torsional amplitude with 
combination of LenSx® and Centurion® (hereafter called LenSx group) 
than conventional cataract surgery (hereafter called Conventional 
group).  
Population 
Adult subjects, 20 years of age or older, with no ocular pathology that 
confound study outcomes, who require cataract extraction by 
phacoemulsification both eye. 
Study design 
Prospective, observer-masked (Specular microscope), randomized, 
within-subject control, single-center study 
Study medical device 
LenSx® 
Endpoints 
Primary Endpoint 

Cumulative Dissipated Energy (CDE)
Secondary Endpoints 

Percent change of corneal endothelial cell density (ECD) at Visit
5 from Pre-Operative Visit

Average torsional amplitude
 
Safety Endpoints 

Average Events

Device Deficiencies
Usage 
To be used in cataract surgery for continuous curvilinear capsulorrhexis 
(CCC) and lens fragmentation

Protocol No.: CTB258-P001 
2/33 
 
2 
 
Examination/observation 
schedule 
Observation schedule 
 
Visit 0 (within 60 days before surgery) 
 
Visit 00 (surgery day, during surgery) 
 
Visit 1 (1 day after surgery) 
 
Visit 2 (4-10 days after surgery) 
 
Visit 3 (20-40 days after surgery) 
 
Visit 4 (60-120 days after surgery) 
 
Visit 5 (150-210 days after surgery) 
Target sample size 
55 subjects (50 subjects for analyses) 
LenSx group and Conventional group will be randomly allocated to 
either eye within a subject.  
Planned study period 
May 2018 to June 2019 
(registration period: May 2018 to October 2018) 
Sponsor 
Alcon Japan Ltd. 
Regulatory requirements In principle, this study will be conducted in accordance with the Good 
Clinical Practice (GCP) and Ethical Guidelines for Clinical Studies 
(2014, Ministry of Education, Culture, Sports, Science and Technology 
and Ministry of Health, Labour and Welfare Notification No.3). 
 

Protocol No.: CTB258-P001 
3/33 
 
3 
 
Table of contents 
 
1 
INTRODUCTION ...................................................................................................................... 5 
1.1 Circumstances ............................................................................................................................ 5 
1.2 Summary of Known and Possible Risks and Benefits for Subjects .......................................... 6 
2 
STUDY OBJECTIVES ............................................................................................................... 6 
3 
TEST ARTICLE .......................................................................................................................... 6 
3.1 Test Article ................................................................................................................................. 6 
3.2 Usage ......................................................................................................................................... 6 
3.3 Instroction on Packaging and Labeling .................................................................................... 6 
3.4 Storage and Management .......................................................................................................... 6 
4 
SUBJECTS ................................................................................................................................. 6 
4.1 Estimated Total Sample Size ................................................................................................... 6 
4.2 Inclusion Criteria ....................................................................................................................... 6 
4.3 Exclusion Criteria ...................................................................................................................... 7 
5 
STUDY DESIGN ........................................................................................................................ 8 
5.1 Surgical Technique .................................................................................................................... 8 
6 
STUDY PROCEDURES ............................................................................................................ 9 
6.1 Outline ....................................................................................................................................... 9 
6.2 Method of Subject Selection ..................................................................................................... 9 
6.3 Examination/Observation Schedule ........................................................................................ 11 
6.4 Examinations/Observations ..................................................................................................... 12 
6.5 Planned Study Period .............................................................................................................. 15 
7 
CONCOMITANT THERAPIES ............................................................................................... 15 
8 
DISCONTINUED SUBJECTS ................................................................................................. 15 
8.1 Discontinued Subjects ............................................................................................................. 15 
8.2 Discontinuation of the Entire Study ........................................................................................ 15 
9 
STATISTICAL ANALYSIS ...................................................................................................... 16 
9.1 Subject Evaluability ................................................................................................................ 16 
9.2 Datasets .................................................................................................................................... 16 
9.3 Demographic Factors and Baseline Characteristics ................................................................ 17 
9.4 Efficacy Analysis ..................................................................................................................... 17 
9.5 Handling of Missing Data ....................................................................................................... 19 
9.6 Multiplicity .............................................................................................................................. 19 
9.7 Safety Analysis ........................................................................................................................ 19 
9.8 Sample Size Justification ......................................................................................................... 20 
10 ADVERSE EVENTS AND DEVICE DEFICIENCIES, etc. ................................................... 20 
10.1 General Information ............................................................................................................... 20 
10.2 Procedure for Reporting of serious adverse events (SAE) ..................................................... 22 

Protocol No.: CTB258-P001 
4/33 
 
4 
 
10.3 Report of adverse events and evaluation of the causal relationship ....................................... 22 
10.4 Intensity Assessment of Adverse Events ................................................................................ 23 
10.5 Follow-up of Subjects / Subjects with Adverse Events .......................................................... 23 
10.6 Subject Pregnancy.................................................................................................................. 23 
10.7 Provision of Safety Information ............................................................................................. 23 
11 
ETHICS .................................................................................................................................... 23 
11.1 Independent Ethics Committee ................................................................................................ 23 
11.2 Ethical Consideration .............................................................................................................. 24 
11.3 Protection of Subjects’ Privacy................................................................................................ 24 
11.4 Specifications to Secure Safety of Study Subjects .................................................................. 24 
11.5 Compensation for Health Hazards ........................................................................................... 24 
11.6 Payment to SFubjects .............................................................................................................. 25 
12 PROTOCOL AMENDMENTS ................................................................................................. 25 
13 CONSIDERATIONS FOR DOCUMENTATION AND COMPLETION OF CASE REPORT 
FORM ....................................................................................................................................... 25 
14 MONITORING ......................................................................................................................... 25 
15 RETENTION OF THE RECORDS .......................................................................................... 25 
16 CONFIDENTIALITY AND PUBLICATION OF STUDY...................................................... 26 
17 DIRECT ACCESS TO SOURCE DATA AND DOCUMENTS ............................................... 26 
18 QUALITY CONTROL AND QUALITY ASSURANCE OF THE STUDY ........................... 26 
19 OBLIGATIONS OF INVESTIGATORS .................................................................................. 26 
20 INFORMED CONSENT .......................................................................................................... 30 
21 CONFLICT OF INTEREST ..................................................................................................... 32 
 

Protocol No.: CTB258-P001 
5/33 
 
5 
 
1 INTRODUCTION 
1.1 Circumstances 
   In recent years, the efficiency and safety of cataract surgery has improved as 
phacoemulsification machines and intraocular lenses become more advanced. The recent 
introduction of femtosecond laser has led to improved surgical accuracy and efficiency through the 
use of femtosecond laser assisted cataract surgery (FLACS) in keratotomy, anterior capsulotomy, 
nucleus fragmentation etc.1, 2. Many of the reports highlight FLACS for its repeatability and 
precision. It allows making a corneal incision wound as planned and continuous curvilinear 
capsulorrhexis (CCC) close to perfect circle3. Laser nucleus fragmentation is associated with 
reduced ultrasonic energy than manual surgery, but superiority of outcomes using FLACS has not 
been established because wide variety of FEMTO and Phaco systems, fragmentation patterns, and 
various settings of Phaco parameters were used in previous studies.  
   One of the endpoints for clinical evaluation in cataract surgery is corneal endothelial cell density 
(EDC) change. To date, techniques4, 5 and ophthalmic viscoelastic devices (OVD)6 have been 
developed for the protection of corneal endothelial cells. The reported possible factors for corneal 
endothelial cell reduction in cataract surgery include long ultrasonic treatment time and high mean 
ultrasonic power7. 
   FLACS allows finer lens nucleus fragmentation, making it possible to reduce ultrasonic power 
and ultrasonic treatment time as compared to conventional manual cataract surgery. Thus, we may 
expect lower corneal EDC reduction rates. 
The purpose of this study (CTB258-P001) is to demonstrate the efficacy of LenSx® in cataract 
surgery by comparing FLACS with minimum grid (200 μm) of lens fragmentation with 
combination of the latest LenSx® and Centurion® combination to manual conventional surgery 
without LenSx®. 
 
   In principle, this study will be conducted in accordance with the Good Clinical Practice (GCP) 
                                                   
1 Zoltan Nagy, Agnes Takacs, Tamas Filkorn, et al. Initial Clinical Evaluation of an Intraocular 
Femtosecond Laser in Cataract Surgery. J. Refractive Surg. 2009; 25:1053-60 
2 Neil J. Friedman, Daniel V. Palanker, Georg Schuele, et al. Femtosecond laser capsulotomy. J 
Cataract Refract Surg 2011; 37:1189–1198 
3 Kasu Prasad Reddy, Jochen Kandulla, Gerd U. Auffarth, Effectiveness and safety of femtosecond 
laser–assisted lens fragmentation and anterior capsulotomy versus the manual technique in cataract 
surgery. J Cataract Refract Surg 2013; 39:1297–1306 
4 Pirazzoli G, D’Eliseo D, Ziosi M, et al. Effects of phacoemulsification time on the corneal 
endothelium using phacofracture and phaco chop techniques. J Cataract Refract Surg. 1996; 
22:967-969 
5 Miyata K., Nagamoto T., Maruoka S., et al. Efficacy and safety of the soft-shell technique in 
cases with a hard lens nucleus. J Cataract Refract Surg 2002; 28:1546–1550 
6 Steele AD1, Andrews V. Methylcellulose for endothelial cell protection. Aust N Z J Ophthalmol. 
1988; 16: 251-254 
7 宮井尊史、宮田和典. 白内障手術と角膜内皮. IOL&RS 2006; 4: 367-371 

Protocol No.: CTB258-P001 
6/33 
 
6 
 
and Ethical Guidelines for Clinical Studies (2014, Ministry of Education, Culture, Sports, Science 
and Technology and Ministry of Health, Labour and Welfare Notification No.3). 
 
1.2 Summary of Known and Possible Risks and Benefits for Subjects 
See Appendix B “package insert.” 
 
2 STUDY OBJECTIVES 
   To demonstrate less Cumulative Dissipated Energy (CDE), lower endothelial cell less and lower 
average torsional amplitude with combination of LenSx® and Centurion® (hereafter called LenSx 
group) than conventional cataract surgery (hereafter called Conventional group).  
 
3 TEST ARTICLE 
3.1 Test Article 
LenSx® 
For details of the study medical device, see Appendix B “Package insert.” 
 
3.2 Usage 
   Connect SoftFit® patient interface to the study medical device. Applanate the study eye using 
SoftFit® patient interface and set incision pattern parameters on the study medical device. Perform 
anterior capsulotomy and lens fragmentation. Disconnect SoftFit® patient interface from the study 
eye and perform phacoemulsification and intraocular lens insertion after making a main incision 
with a slit knife. 
 
3.3 Instruction on Packaging and Labeling 
Not applicable 
 
3.4 Storage and Management 
For the storage method, see the instruction manual. 
 
4 SUBJECTS 
4.1 Estimated Total Sample Size 
55 subjects (50 subjects for analyses) 
LenSx group and Conventional group will be randomly allocated to either eye within a subject.  
 
4.2 Inclusion Criteria 
Patients meeting all of the following 1)-6) 
1) Adults, 20 years of age or older at the time of informed consent, of either gender, diagnosed 
with cataracts with planned cataract removal by phacoemulsification in both eye. 
2) Able to comprehend and willing to sign informed consent and complete all required 

Protocol No.: CTB258-P001 
7/33 
 
7 
 
postoperative follow-up procedures. 
3) Calculated lens power within the available range. 
4) Potential postoperative Best Corrected Distance visual acuity (BCDVA) of 0.7 decimal or better 
in study eye based on Investigator expert medical opinion. 
＊ NOTE: Subjects with any pathology that could reduce visual potential should not be 
enrolled in this study. 
5) Clear intraocular media other than cataract in both eyes 
6) Cataract grade is Grade 2-4 of Emery-Little Classification. 
 
[Rationale for the inclusion criteria] 
1) and 3): To confirm the eligibility for this study. 
2): To ensure that subjects understand the risks associated with participation in the clinical study  
   and that adequate informed consent is obtained and to enable complete collection of all  
   follow-up study data. 
4): To ensure that subjects have the possibility for achieving improved vision postoperatively 
5): To select patients who has eligibility of laser procedure 
6): To avoid bias of procedure difficulty 
 
4.3 Exclusion Criteria 
Exclusion criteria (Prior to Surgery) 
Patients meeting any of the following 1)-16). 
1) Corneal opacity that would interfere with the laser beam 
2) Hypotony or the presence of a corneal implant 
3) Residual, recurrent, active ocular or eyelid disease, including any corneal abnormality (for 
example, recurrent corneal erosion, etc.) 
4) Corneal disease that precludes applanation of the cornea or transmission of laser light at 1030 
nm wavelength 
5) Descemetocele with impending corneal rupture 
6) Presence of blood or other material in the anterior chamber 
7) Poorly dilating pupil, such that the iris is not peripheral to the intended diameter for the 
capsulotomy 
8) Conditions which would cause inadequate clearance between the intended capsulotomy depth 
and the endothelium 
9) Any contraindication to cataract 
10) Corneal endothelial cell density is less than 2000 cells/mm2 
11) Presence of peripheral iridotomy 
12) Patients whose cataract grade of both eyes are two different levels 
13) Pregnancy current or planned during the course of the study 
14) Any subject currently participating in another investigational drug or device study that may 
confound the results of this investigation 
15) Subjects who are expected to require an ocular surgical treatment at any time during the study 

Protocol No.: CTB258-P001 
8/33 
 
8 
 
(other than Nd:YAG capsulotomy) 
16) Disqualified by the investigator or the sub investigator because of systemic or ophthalmic 
diseases 
 
[Rationale for the exclusion criteria] 
1)-9): contraindication/prohibition of the test devise 
10) and 11): To avoid factors potentially affecting the secondary efficacy endpoints 
12): To avoid the risk of creating a difference in background of both groups 
The other criteria were established for general safety consideration. 
 
Exclusion criteria (During Surgery) 
Patients whose study eye meets any of the following 1)-6). 
1) Eyes with any other additional procedures during the cataract surgery and IOL implant due to 
intraoperative complications that required further intervention (including but not limited to 
posterior capture rupture, vitreous loss, etc.) 
2) Incomplete CCC by LenSx 
3) Significant anterior chamber bleeding 
4) Uncontrolled intraocular pressure 
5) Bag-sulcus, sulcus-sulcus or unknown placement of the haptics 
6) Disqualified by the investigator or the sub investigator because of any clinical reason (adverse 
event etc.) 
 
[Rationale for the exclusion criteria] 
To avoid factors potentially affecting the primary and secondary efficacy endpoints 
 
5 STUDY DESIGN 
Prospective, observer-masked (specular microscope only), randomized, within-subject control, 
single-center study 
 
5.1 Surgical Technique 
The surgical techniques of LenSx group and Conventional group are as follows. For the selection of 
surgeon, see Appendix C.  
1) LenSx surgical technique 
LenSx® is used for CCC and lens fragmentation procedure of cataract surgery in this study. 
Use a slit knife (2.6 mm) to make a main incision by keratotomy, and insert an intraocular 
lens (IOL, Alcon®UltraSert®AcrySof®IQ Single Piece (Alcon Japan Ltd.)) after 
phacoemulsification using the Centurion® VISION SYSTEM (Alcon Japan Ltd.). The laser 
parameters and phaco parameters will be set as described in Section 6.4 2). 
If the LenSx surgery is tried but fails to be completed, perform the manual surgical 
technique. 

Protocol No.: CTB258-P001 
9/33 
 
9 
 
2) Conventional surgical technique 
CCC and fragmentation will be conducted manually. Use a slit knife (2.6 mm) to make a 
main incision by keratotomy, and insert IOL (Alcon®UltraSert®AcrySof®IQ Single Piece 
(Alcon Japan Ltd.)) after phacoemulsification using the Centurion® VISION SYSTEM 
(Alcon Japan Ltd.). The phacoemulsification parameters will be set as described in Section 
6.4 2). 
 
6 STUDY PROCEDURES 
6.1 Outline 
   The population is patients undergoing cataract surgery by phacoemulsification whose cataract 
grade is diagnosed as grade 2, 3 or 4 (Emery-Little classification). One eye will be assigned to the 
LenSx group and the other eye to the Conventional group in a random manner according to the 
randomization table8 for cataract surgery. The randomization information will be masked only to 
the specular microscope observer9. Examinations and observations will be performed prospectively 
from before surgery until around 6 months after surgery. The target sample size is 55 subjects. 
 
6.2 Method of Subject Selection 
Subjects will be selected will be following method. 
 
Figure 6-1  Outline of This Study 
 
 
1) After explanation of the content of study to subject, obtain consent to participate in the clinical 
study from subject. 
                                                   
8 The person in charge of randomization will prepare a randomization table using the permuted 
block method. 
9 A person different from the surgeon will be designated as the specular microscope observer 
before the start of the study. Specular microscope will be observed by a single observer. The 
specular microscope observer will assure that masking was maintained by signing the “confirmation 
of masking” after the end of the study. 
Postoperative examinations
Cataract surgery and IOL implantation
Surgical procedure assignment
Inclusion/ Exclusion criteria
Informed consent, subject ID code assignment

Protocol No.: CTB258-P001 
10/33 
 
10 
 
2) Subject code will be assigned after obtain consent. 
3) Perform examinations/observations (screening tests) necessary for the investigator etc. to 
assess eligibility according to the inclusion/exclusion criteria and the investigator will assess 
the qualification. 
4) For qualified subjects, LenSx group or Conventional group will be allocated to either eye 
according to the randomization table. 
5) Perform cataract surgery. 
The eye with more aggravated cataract will be operated first. If both eyes are the same, then 
always pick the right eye. Subjects will be assessed according to the intraoperative exclusion 
criteria during the surgery. 
6) Perform the postoperative examinations. 
 

Protocol No.: CTB258-P001 
11/33 
 
11 
 
6.3 Examination/Observation Schedule 
   As shown in Table 6-1, the examination and observation are carried out for the period from 
within 60 days before surgery to 150-210 days after surgery. 
 
Table 6-1 Overview of Study Procedure 
  
Visit 0 
Visit 00 
Visit 1 
Visit 2 
Visit 3 
Visit 4 
Visit 5 
Procedure/Assessment 
Day -60 
Surgery day, 
during 
surgery 
Day 1 
Day 4-10 
Day 20-40 
Day 60-120 
Day 150-210 
Informed Consent 
X 
  
  
 
  
  
Demographics 
X 
  
  
 
  
  
Medical History 
X 
  
  
 
  
  
Inclusion/Exclusion 
X 
X 
  
 
  
  
Corneal Endothelial Cell 
X 
  
  
 
X 
  
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
CDE 
  
X 
  
 
  
  
Average Torsional 
Amplitude 
 
X 
 
 
 
 
 
 
  
 
  
 
  
  
 
 
 
 
 
 
 
 
Slit Examination 
X 
  
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
X 
Device Deficiency 
  
X 
X 
X 
X 
X 
X 
Adverse Experiences 
X 
 
 
 
 
 
 
 
 
 
 
 

Protocol No.: CTB258-P001 
12/33 
 
12 
 
6.4 Examinations/Observations 
  The following examinations/observations will be performed at Visit 0 (before surgery), Visit 00 
(surgery day), Visit 1 (1 day after surgery), Visit 2 (4-10 days after surgery), Visit 3 (20-40 days 
after surgery), Visit 4 (60-120 days after surgery) and Visit 5 (150-210 days after surgery). The 
same instruments and methods should be used for all measurements at all visits in a site. 
  
1) Visit 0 (Before surgery) 
   The investigator should provide an adequate explanation to subjects on this study to obtain 
written voluntary consent from them. Each subject who has provided consent will be given a 
subject ID code and assessed according to the inclusion/exclusion criteria.  
 
   After consent, the following examinations/observations will be performed. Results of general 
examinations performed for cataract surgery before consent may be adopted as clinical study 
data if they are obtained within 60 days before surgery. 
 
 Demography 
Sex, age (at consent), ophthalmic medical history, ophthalmic surgical history, and 
ophthalmic complications will be investigated. 
 
 Specular microscope (observer-masked) 
The central corneal endothelial cell density,
 
 will be measured. These observations will 
be performed by the same observer masked to randomization information, who is not the 
surgeon. 
 
 
 
 
 
 
 
 
 
 
 Slit lamp Examination 
The eye condition will be observed by the slit lamp microscopy. The presence or absence of 
clinically significant ophthalmologic findings will be recorded.  
The lens condition will be graded according to the Emery-Little classification (Appendix D). 
 
 Preoperative adverse experiences 
Adverse experiences occurring from consent to before surgery will be recorded. 

Protocol No.: CTB258-P001 
13/33 
 
13 
 
2) Visit 00 (Surgery day, during surgery) 
Confirm the assigned surgical techniques. 
 
 
Exclusion criteria (during surgery) 
Confirm the exclusion criteria of during surgery. 
 
 
Femtosecond laser surgery device 
LenSx® (Alcon Japan Ltd.) will be used. The same software version of LenSx® should be 
used for all subjects. The parameters will be set as follows. 
 
LENS PARAMETERS 
LENS METHOD 
FRAG 
DIAMETER 
6.0 mm 
ENERGY 
15.00 μJ 
SPOT SEPARATION 
20 μm 
LAYER SEPARATION 
30 μm 
FRAG SIZE 
200 μm 
 
CAPSULOTOMY PARAMETERS 
DIAMETER 
5.5 mm 
ENERGY 
7.00 μJ 
SPOT SEPARATION 
5 μm 
LAYER SEPARATION 
4 μm 
 
 
Recording of surgical techniques 
The surgical techniques of anterior capsulotomy and lens fragmentation will be recorded. 
“Anterior capsulotomy” 
01 – Completed with the assigned surgical techniques 
02 – Not completed with the assigned surgical techniques 
 
“Lens fragmentation” 
01 – Completed with the assigned surgical techniques 
02 – Not completed with the assigned surgical techniques 
 
 
 
Incision making 
In both of the groups, the corneal incision (main incision) will be made by using a slit knife 
(2.6 mm). Side ports may also be made if necessary. 

Protocol No.: CTB258-P001 
14/33 
 
14 
 
 
Ophthalmic viscoelastic device (OVD) 
PROVISC® (Alcon Japan Ltd.) will be used as the OVD. However, other OVDs may be 
added if medically considered necessary for adverse events or the prevention of adverse 
events. 
 
 
Intraocular irrigation solution 
BSS PLUS® Irrigating Solution 0.0184% (Alcon Japan Ltd.) will be used as the intraocular 
irrigation solution. 
 
 
Phacoemulsification 
A cataract surgery device called CENTURION® VISION SYSTEM (Alcon Japan Ltd.) will 
be used for phacoemulsification. The parameters will be set as follows. 
 
Phaco power (%) 
0 
Torsional power (%) 
50 
Vacuum (mmHg) 
600 
Aspiration flow (mL/min) 
40 
Ultrasonic mode (pulse) 
Continuous 
 
 
 
 
 
 
 
IOL insertion 
Alcon® UltraSert® AcrySof® IQ Single Piece (Alcon Japan Ltd.) will be inserted. 
 
 
Cumulative Dissipated Energy (CDE) 
CDE will be recorded after the U/S portion. 
 
 
Average torsional amplitude 
The average torsional amplitude will be recorded after the U/S portion.  
 
 
 
 
 
 
 
 
 

Protocol No.: CTB258-P001 
15/33 
 
15 
 
 
Adverse events, device deficiencies 
Adverse events and device deficiencies will be recorded. 
 
3) Visits 1, 2, 3, 4, 5 (after surgery) 
 
Specular microscope (observer-masked) (Visit 5) 
The central corneal endothelial cell density, 
 
 These observations 
will be performed by the same observer masked to randomization information, who is not the 
surgeon. 
 
 
 
 
 
 
 
 
 
 
 
Slit lamp microscopy 
The presence or absence of clinically significant ophthalmologic findings will be recorded. 
 
 
Adverse events and device deficiencies 
Adverse events and device deficiencies will be recorded. 
 
4) Unscheduled Visits Examinations 
When a subject makes an unscheduled visit for adverse events etc., inquire about the reason 
for the visit and retain the record. The investigator will perform examinations/observations 
those are necessary and retain the record. 
 
6.5 Planned Study period 
May 2018 to June 2019 
 
7 CONCOMITANT THERAPIES 
No concomitant therapy will be prohibited. 
 
8 DISCONTINUED SUBJECTS 
8.1 Discontinued Subjects 
The subject is discontinued in the following cases: 
1) Upon onset of adverse events which make study continuation difficult. 
2) Upon cancellation of the subject to discontinue the study. 

Protocol No.: CTB258-P001 
16/33 
 
16 
 
3) Upon request of the subject to discontinue the study. 
4) Continuation of the study was judged as impossible because of subject’s referral or move during 
the study. 
5) Other, if the investigators judge it necessary to discontinue this study. 
 
   Upon discontinuation of the study, if the investigator or sub-investigator decided the 
examination or observation is necessary, the examination or observation should be carried out as far 
as possible under the subject’s consent, and the reason of discontinuation are entered in the case 
report form.  
   In case where continuation of the study is difficult because of discontinued visit of the subject to 
the clinic, the subject is followed over telephone, by mail or other appropriate means and the reason 
for discontinued visit, survival/death of the subject, presence/absence of adverse events, etc., are 
entered in the case report form. 
 
8.2 Discontinuation of the Entire Study 
   If discontinuation of the entire study has become inevitable for reasons of reports on serious 
safety information, problems pertaining to the quality of the test articles, and so on, the Sponsor is 
required to immediately inform the investigator and the head of each study site of discontinuation of 
the study and its reason in writing. 
 
9 STATISTICAL ANALYSIS 
9.1 Subject Evaluability 
   Subject evaluability based on pre-specified deviations and their impact on analysis sets will be 
determined prior to database lock. 
 
9.2 Datasets 
The data sets for the efficacy and safety analyses in this study are defined as follows. 
1) Safety Analysis Set 
   The Pre-Treatment Safety Analysis Set will include all subjects who consented to participate in 
the study. The Pre-Treatment Safety Analysis Set will be the set that will be used to summarize 
occurrence of adverse experiences prior to cataract surgery using test device. The 
Treatment-Emergent Safety Analysis Set will include all eyes for which cataract surgery is 
performed with test device (regardless of success or failure). 
 
2) Full Analysis Set (FAS) 
   The FAS will include eyes with successful cataract surgery for which anterior capsulotomy and 
lens fragmentation have been completed using the assigned surgical techniques. 
 
3) Per Protocol Set (PPS) 

Protocol No.: CTB258-P001 
17/33 
 
17 
 
   The PPS will include all eyes with successful cataract surgery for which anterior capsulotomy 
and lens fragmentation have been completed using the assigned surgical techniques and meeting the 
following conditions, data of at least one postoperative observation are available, and the study 
medical device has been successfully inserted. 
 
at least 1 postoperative visit; and 
 
no major protocol violation. The PPS will exclude visits by individual subjects and 
observed data that do not meet the clinical study protocol criteria. 
 
   The Pre-Treatment Safety Analysis Set will be the set that will be used to summarize occurrence 
of adverse experiences prior to exposure to cataract surgery using test device. The 
Treatment-Emergent Safety Analysis Set will be used for safety analysis after cataract surgery 
using test device. 
   The FAS and PPS will be used for primary effectiveness analysis in the study, with priority 
given to FAS results.  
 
 
9.3 Demographic Factors and Baseline Characteristics 
   For all analysis datasets (Safety Analysis Set, FAS and PPS), demographics (sex, age, cataract 
grade) will be summarized. For sex and cataract grade, the N and percentage will be summarized. 
For age (<60, 60-69, 70-79, ≥ 80), the N and percentage, and descriptive statistics (arithmetic mean,  
standard deviation, N, median, minimum and maximum) will be summarized. 
 
9.4 Efficacy Analysis 
   The objective of this study is to demonstrate superiority of less-invasiveness of LenSx group to 
Conventional group.. 
 
9.4.1 Primary analysis 
The primary endpoint is Cumulative Dissipated Energy (CDE) at Visit 00 (surgery day). 
 
9.4.1.1 Statistical hypotheses 
   The null hypothesis (H0) and the alternative hypothesis (H1) for the primary 
analysis are as follows. 
 
H0 : (𝐿𝑒𝑛𝑆𝑥) = (𝐶𝑜𝑛𝑣) 
H1 : (𝐿𝑒𝑛𝑆𝑥) < (𝐶𝑜𝑛𝑣) 
 
, where each of (𝐿𝑒𝑛𝑆𝑥) and (𝐶𝑜𝑛𝑣) denotes the mean of CDE for LenSx and 
Conventional surgery in population. 
 
9.4.1.2 Analysis methods 

Protocol No.: CTB258-P001 
18/33 
 
18 
 
   The descriptive statistics of CDE at Visit 00 (surgery day) will be calculated for 
each of the surgical techniques (arithmetic mean, standard deviation, N, median, 
minimum and maximum) and the means will be estimated using 95% confidence 
intervals based on the MMRM (mixed model for repeated measures). The superiority 
of LenSx to Conventional will be tested if there is a significant difference in mean 
between the surgical techniques (MMRM-based t-test, significance level: one-sided 
2.5%). 
 
 
9.4.2 Secondary efficacy analysis 
The secondary endpoints are as follows. 
 
Percent change of corneal endothelial cell density (ECD) at Visit 5 (150-210 days 
after surgery) from Pre-Operative Visit 
 
Average torsional amplitude at Visit 00 (surgery day) 
 
9.4.2.1 Statistical hypotheses 
   The null hypothesis (H0) and the alternative hypothesis (H1) for the secondary 
analysis are as follows. 
 
< Percent ECD change (Visit 5) > < Average torsional power (Visit 00) > 
H0 : (𝐿𝑒𝑛𝑆𝑥) = (𝐶𝑜𝑛𝑣)  
H0 : (𝐿𝑒𝑛𝑆𝑥) = (𝐶𝑜𝑛𝑣) 
H1 : (𝐿𝑒𝑛𝑆𝑥) > (𝐶𝑜𝑛𝑣)  
H1 : (𝐿𝑒𝑛𝑆𝑥) < (𝐶𝑜𝑛𝑣) 
 
, where each (𝐿𝑒𝑛𝑆𝑥) and (𝐶𝑜𝑛𝑣) denotes the means of the parameters for LenSx 
and Conventional surgery in population. 
 
9.4.2.2 Analysis methods 
   The descriptive statistics of ECD, absolute and percent ECD change and average 
torsional power will be calculated for each of the surgical techniques (arithmetic mean, 
standard deviation, N, median, minimum and maximum) and the means will be 
estimated using 95% confidence intervals based on the MMRM (mixed model for 
repeated measures). The hypothesis on percent ECD change from before surgery to 
Visit 5 (150-210 days after surgery) will be tested only if the superiority is 
demonstrated in the primary analysis. The hypothesis on average torsional power at 
Visit 00 (surgery day) will be tested only if there is a significant difference in percent 
ECD change (both MMRM-based t-test, significance level: one-sided 2.5%). 
 
 
 

Protocol No.: CTB258-P001 
19/33 
 
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
9.5 Handling of Missing Data 
Missing data will not be imputed. 
 
9.6 Multiplicity 
   In the primary analysis, multiplicity will not be an issue since there is only one primary 
endpoint. For the 2 secondary endpoints, the hypotheses will be tested in the pre-specified order 
only if the superiority is demonstrated in the primary analysis. Therefore, the type I family-wise 
error (FWE) for the total of 3 hypothesis tests (primary analysis (once) and secondary analysis 
(twice)) is controlled (one-sided 2.5%). 
 
 
 
9.7 Safety Analysis 
   Lists of untoward safety events occurring from consent to before cataract surgery will created. 
The incidences and proportions of adverse events and deficiencies occurring after cataract surgery 
will be calculated by surgical technique. 

Protocol No.: CTB258-P001 
20/33 
 
20 
 
 
9.8 Sample Size Justification 
The 50 evaluable subjects will be enrolled for this study. For CDE, treatment difference was 
assumed 1.9% with common standard deviation of 1.2%. The sample size was simulated in Table 1 
varying correlation coefficient between both eyes because intra-subject positive correlation between 
both eyes is assumed for endpoints in this study. 
 
Table 9.8-1 Statistical Power for CDE (N=50) 
Correlation between Both Eyes 
Actual Power 
0 
>0.999 
0.25 
>0.999 
0.50 
>0.999 
0.75 
>0.999 
0.99 
>0.999 
 
Also, for ECD, treatment difference and common standard deviation of ECD percent change 
from Baseline at Visit 5 was assumed 5.5% with common standard deviation of 11%. The sample 
size was simulated in Table 2 in the same manner as CDE. 
 
Table 9.8-2 Statistical Power for ECD (N = 50) 
Correlation between Both Eyes 
Actual Power 
0 
0.688 
0.25 
0.808 
0.50 
0.934 
0.75 
0.998 
0.99 
>.999 
 
Considering 8% dropout rate, 55 subjects will be enrolled for this study. 
 
10 ADVERSE EVENTS AND DEVICE DEFICIENCIES, etc. 
10.1 General Information 
Refer to the Glossary of Terms below for categories of Adverse Experiences, AEs and SAEs. 
 
Adverse Experience: 
Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects from consent to before cataract 
surgery will be recorded. 
 
Adverse Event (AE): 

Protocol No.: CTB258-P001 
21/33 
 
21 
 
Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects after cataract surgery (including 
during cataract surgery), users or other persons, whether or not related to the 
investigational medical device (test article). For subjects, this definition includes events 
related to the test article or the procedures involved. For users or other persons, this 
definition is restricted to events related to the test article. 
  
Serious Adverse Event: 
Adverse event that led to any of the following, or that needed treatment not to lead to the 
following results: 
・ Death. 
・ A serious deterioration in the health of the subject that either resulted in: 
a) a life-threatening illness or injury. 
Note: Life-threatening means that the individual was at immediate risk of death from 
the event as it occurred, ie, it does not include an event which hypothetically might 
have caused death had it occurred in a more severe form. 
b) any potentially sight-threatening event or permanent impairment to a body 
structure or a body function. 
c) in-patient hospitalization or prolonged hospitalization. 
Note: Planned hospitalization for a pre-existing condition, without serious 
deterioration in health, is not considered a serious adverse event. In general, 
hospitalization signifies that the individual remained at the hospital or emergency 
ward for observation and/or treatment (usually involving an overnight stay) that 
would not have been appropriate in the physician's office or an out- patient setting. 
Complications that occur during hospitalization are adverse events. If a complication 
prolongs hospitalization or fulfills any other serious criteria, the event is serious. 
When in doubt as to whether “hospitalization” occurred, the event should be 
considered serious. 
d) a congenital anomaly/birth defect, 
e) a medically important event or reaction. 
 
Non-serious Adverse Event 
Adverse event that does not meet the criteria for a serious adverse event. 
 Adverse Device Effect (ADE) 
Adverse event related to the use of an investigational medical device (test article).   
Note: This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation; any malfunction; 
and use error or intentional misuse of the test article. 
 

Protocol No.: CTB258-P001 
22/33 
 
22 
 
Serious Adverse Device Effect (SADE) 
Adverse device effect that has resulted in any of the consequences characteristic of a serious 
adverse event. 
 
Device Deficiency 
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, 
safety, or performance. 
 
Safety Information: 
Information about quality, efficacy and safety for medical device and information which is 
needed for appropriate use, including: 
• Use error 
• Abnormal Use 
• Product tampering 
• Product counterfeiting 
• Product theft  
 
10.2 Procedure for Reporting of Serious Adverse Events (SAE) 
   The investigator will report the serious adverse event or the risk of causing serious adverse 
event to Alcon within 24 hours after confirming the event.  
After obtainment of detailed information on the serious adverse event, the investigator will prepare 
a report and immediately submit it to Alcon and the head of the medical institutions. 
 
 
  
 
 
 
When the SAE is correspond to “Death or a life-threatening ADE” or “Serious and unexpected ADE 
other than Death or a life-threatening event”, the sponsor will immediately notify them to heads of 
all medical institutions and all investigators by document. 
 
10.3 Report of Adverse Events and Evaluation of the Causal Relationship 
   All adverse experiences from consent to before cataract surgery and adverse events after signed 
informed consent will be documented on the Adverse Event Case Report Form (CRF). 
For every AE, the investigator will assess the casual relationship of the medical device at “related” 
or “ not related”. 
 

Protocol No.: CTB258-P001 
23/33 
 
23 
 
10.4 Intensity Assessment of Adverse Events 
   For every AE, the investigator must assess the intensity (severity). Events should be classified 
as mild, moderate, or severe. These classifications should be based on the following definitions: 
         Intensity: 
Mild  
An AE is mild if the subject is aware of but can easily tolerate the sign or 
symptom.  
Moderate  
An AE is moderate if the sign or symptom results in discomfort significant 
enough to cause interference with the subject’s usual activities.  
Severe  
An AE is severe if the sign or symptom is incapacitating and results in the 
subject’s inability to work or engage in their usual activities. 
 
10.5 Follow-up of Subjects / Subjects with Adverse Events 
   In the event of acknowledging any adverse events, the investigators should immediately take 
appropriate actions irrespective of the presence or absence of causal relationship with the test article.  
And the investigators will make a follow-up of the adverse event if it is possible.  When the 
subject needs medical treatment, the investigators should inform the subject of the matter.  
For subjects who are experiencing ongoing unresolved adverse events at the time of their study 
completion or early discontinuation from the study, it is recommended that the investigator schedule 
an appropriate follow-up visit in order to determine the outcome of the event. 
 
10.6 Subject Pregnancy 
   Women 
 planning to become pregnant during this study period or women who are 
pregnant at the time of study entry are excluded from participation. 
 
10.7 Provision of Safety Information 
   Investigators provide safety information which is needed to make a detailed report on demand 
from the sponsor. 
 
11 ETHICS 
11.1 Independent Ethics Committee 
Prior to the start of the study, the Independent ethics committee (IEC) of each participating 
institution is required to inspect and evaluate the planned study as to the acceptability of 
implementing the study, appropriateness of the contents of the protocol, case report form, 
questionnaire and informed consent document, and other matters related to the study from the 
ethical, scientific and medical points of view, with an ultimate goal of protecting the human rights 
and welfare of the subjects. 
The inspection and examination by the IEC may be performed again also during a certain period 
of time after the start of the study or when the head of the participating institution sees the necessity 
of additional inspection/examination so that the study may be monitored continuously. 

Protocol No.: CTB258-P001 
24/33 
 
24 
 
 
11.2 Ethical Consideration 
The study is implemented after a contract on implementation of the study is concluded between 
the Sponsor and each participating institution following inspection and authorization of the study by 
the IEC of each participating institution. 
If deemed necessary to ensure safe implementation of the study, the protocol of this study may 
be revised in accordance with the provisions set forth in “Section 12. PROTOCOL 
AMENDMENTS”. 
This study is carried out in accordance with the principles set forth in the Declaration of 
Helsinki and the protocol. This study will be conducted in accordance with GCP and Ethical 
Guidelines for Clinical Studies (2014, Ministry of Education, Culture, Sports, Science and 
Technology and Ministry of Health, Labour and Welfare Notification No.3), in principle. 
 
11.3 Protection of Subjects’ Privacy 
To protect the privacy of individual subjects, only identification codes is used to represent the 
subjects whose data are used in case reports, etc., so that leakage of the identifiable individual 
information about the subjects can be prevented.  
 
11.4 Specifications to Secure Safety of Study Subjects 
1) Actions to take for adverse events 
In the event of acknowledging any adverse events, the investigator or the subinvestigator should 
immediately take appropriate actions irrespective of the presence or absence of causal relationship 
with the test article. 
 
2) Supply of new information 
In the case of obtaining safety-related new and significant information related to the clinical trial, 
the sponsor should supply the information in writing to the investigator and the subinvestigator and 
the head of the study site and take necessary actions. 
 
3) Avoiding emergent risks 
In the event of deviating from the study protocol to avoid the emergent risk and secure safety of 
the study subject or because of other unavoidable clinical reasons, the investigator will retain the 
record and submit the  documentation and justification of the protocol deviation to the sponsor and 
the head of the study site. 
 
11.5 Compensation for Health Hazards 
If any subject has sustained health hazards arising from this study, best healthcare is provided to 
that subject. The Sponsor needs to be covered by insurance for liability arising from clinical trial. 
 

Protocol No.: CTB258-P001 
25/33 
 
25 
 
11.6 Payment to Subjects 
 the Sponsor pays an amount of 
money, predetermined through negotiation with each participating medical institution, to each 
subject. This payment is not intended to force any subject to remain in the study. 
 
12 PROTOCOL AMENDMENTS 
When the protocol, etc. are revised, the sponsor and the investigator will exchange an agreement 
in writing.  Subjects are enrolled, depending on the necessity. 
 
13 CONSIDERATIONS FOR DOCUMENTATION AND COMPLETION OF 
CASE REPORT FORM 
The investigator, etc. will complete the case report form by himself or herself based on source 
data in accordance with the protocol and the preparation procedure of the case report form. After 
preparation of the case report form, he or she will sign and date it, and submit it to the sponsor 
through the person in charge of monitoring. 
 
14 MONITORING 
The Sponsor will designate a monitor to conduct the appropriate site visits at the appropriate 
intervals. The clinical investigation will be monitored to ensure that: 
- The rights and well-being of the subjects are protected. 
- The reported data are accurate, complete, and verifiable from the source documents. 
- The study is conducted in compliance with the current approved protocol (and 
amendment[s], if applicable), with current GCP, Ethical Guidelines for Clinical Studies 
and with applicable regulatory requirements, in principle. 
 
The monitor will report the monitoring results to study manager. 
 
15 RETENTION OF THE RECORDS 
The records for this clinical study shall be stored properly: At expiration of the retention period 
of the records, the sponsor will notify the medical institutions thereof. 
Medical institutions and investigators shall preserve the protocol, source documents, informed 
consent forms agreed, informed consent form and other written information, records on GCP and 
Ethical Guidelines for Clinical Studies (2014, Ministry of Education, Culture, Sports, Science and 
Technology and Ministry of Health, Labour and Welfare Notification No.3). Above documents 
excluding medical records should be retained either five years after the date of completion of the 
study, or three years after the date of publication/presentation the final study result whichever date 
is later. The storage period of clinical record depend on Medical Practitioners Act and other related 
regulations. 
 

Protocol No.: CTB258-P001 
26/33 
26 
16 CONFIDENTIALITY AND PUBLICATION OF STUDY 
All information related to this clinical study including the protocol and therapeutic results are 
the property of the sponsor, and the investigator and other medical staff engaged in the clinical 
study must keep such information confidential. 
The sponsor can submit the results of this clinical study to the health authority and use the 
results as “Information on Proper Use” of the product. Sponsor will register the summary of the 
study to open database (The Database Center of the National University Hospitals, JAPIC Clinical 
Trials Information, or JMACCT Clinical Trials Registry, etc.) before conducting the study, and will 
properly update it based on the revision of the protocol or study progression.  
When publishing the results of this clinical study in the congresses or medical journals, the 
investigators and other medical staff must obtain prior approval from the sponsor.  The sponsor 
can confirm the contents of presentation beforehand. 
After completion of the study, sponsor and the investigators will report the result of the study 
after taking necessary steps for protecting the right and benefits of the subjects, related persons, 
sponsor, investigators, and so on. 
17 DIRECT ACCESS TO SOURCE DATA AND DOCUMENTS 
The investigator and the study site must make source data available to the sponsor or the 
regulatory authority at their request. Such direct access to source data will be performed so that the 
sponsor or the regulatory authority may confirm whether the clinical study is conducted in 
accordance with the protocol and whether data of the case report form are indicated accurately. 
With reference to [Evaluation] and [Comment of the investigator, etc.], there are no source data 
and they are information directly indicated on the case report form. 
18 QUALITY CONTROL AND QUALITY ASSURANCE OF THE STUDY 
Quality control and Quality assurance shall be carried out in accordance with GCP standard 
operational procedures (SOP) and Quality assurance SOP of the Sponsor. 
Quality Assurance will evaluate that the study is properly conducted according to 
the protocol, Standard Operation Procedures of Medical Affairs/ Clinical Development 
Group / Clinical Biometrics, GCP and Ethical Guidelines for Clinical Studies  (2014, 
Ministry of Education, Culture, Sports, Science and Technology and Ministry of Health, 
Labour and Welfare Notification No.3) and its amendments. 
19 OBLIGATIONS OF INVESTIGATORS 
Selection of Trial Subjects 
In the selection of trial subjects, investigator(s) and sub-investigators shall, from the standpoint 
of human rights and on the basis of the standards for selection and exclusion set forth in the trial 
protocol(s), carefully consider whether to request participation in the trial, taking into consideration 

Protocol No.: CTB258-P001 
27/33 
 
27 
 
such factors as the subject’s general state of health, symptoms, age, sex, capacity to consent, 
dependency on investigator(s), etc., and participation in other trials. 
 
Obtaining Consent of Subjects 
Investigator(s) and sub-investigators shall obtain consent for the subject to participate in the trial 
from the subject or legally acceptable representative thereof, in accordance with GCP.  
 
Medical Treatment of Subjects 
The investigator shall have the responsibility for all decisions on medical treatment relating to 
the trial. 
The director of the institution and the investigator shall ensure that the subject is provided with 
adequate medical treatment for all trial-related adverse events that constitute clinical problems 
during and after the subject’s participation in the trial.  Further, when an investigator or 
sub-investigator becomes aware of the need for medical treatment of an adverse event, he or she 
shall so inform the subject. 
Investigator(s) and sub-investigators shall inform the subject’s the primary physician about the 
subject’s participation in the trial if the subject has a primary physician and if the subject agrees to 
the primary physician being informed. 
If a subject desires to withdraw or withdraws participation during the trial, the subject is not 
obliged to clarify the reason for withdrawal, but the investigator or sub-investigator shall make 
appropriate efforts, based on full respect for the rights of the subject, to determine the reason. 
After this study, the investigator shall provide the best treatment for the subjects using the result 
of this study. 
 
Agreement on and Compliance with Trial Protocol(s) 
Prior to reaching an agreement with the sponsor on the trial protocol(s) and case report forms 
(CRF), the investigator shall confer with the sponsor on the basis of the trial protocol(s), CRF, and 
other required materials and information submitted by the sponsor, and shall give full consideration 
to the ethical and scientific suitability of conducting the trial.  The same shall apply if the trial 
protocol(s) or CRF are revised. 
The investigator shall reach agreement with sponsor on the content of the trial protocol(s) and 
CRFs, and as evidence of agreement to comply with the trial protocol(s), the investigator and 
sponsor shall date and affix their signatures or personal seals to a trial contract or alternative 
document.  The same shall apply if the trial protocol(s) or CRFs are revised, or if, due to a 
directive of the director of the institution based on the opinion the IEC, the trial protocol(s) or CRF 
is corrected. 
 
Submission of Documents to the IEC 
Before and during the trial period, the investigator(s) shall keep current those documents that are 

Protocol No.: CTB258-P001 
28/33 
 
28 
 
subject to review by the IEC and are to be submitted by the investigator(s). If these documents are 
augmented, updates or revised, all must be submitted promptly to the director of the institution. 
 
Directive and Decisions of the Director of the Study site 
When the IEC gives its approval to conduct the trial on condition of certain revisions, and the 
investigator has been informed in writing of the directives and decisions of the director of the 
institution based thereon, the investigator shall commence the trial in accordance with these 
directives and decisions.  
When the IEC gives its approval to continue a trial in progress or to continue a trial on condition 
of certain revisions, and the investigator has been informed in writing of the directives and 
decisions of the director of the institution based thereon, the investigator shall continue the trial in 
accordance with these directives and decisions. 
When the IEC cancels its approval to an item related to a trial in progress (including its 
termination or suspension) and the investigator has been informed in writing of the directives and 
decisions if the director of the institution based thereon, the investigator shall comply with these 
directives and decisions. 
 
Use, etc., of the Investigational Product(s) 
The investigator shall ensure that the investigational product(s) are used only in accordance with 
methods that comply with the approved trial protocol(s). 
 
Deviations etc. from Trial Protocol(s)  
The investigator or sub-investigators shall not undertake any deviation from or modification of 
the trial protocol(s) without prior written agreement between the investigator and the sponsor and 
written approval based on prior inspection by the IEC. This is not, however, applicable in the case 
of changes related solely to cases that are medically unavoidable in order to avoid imminent danger 
to the subject, or in the case of management matters (e.g., a change in telephone number). 
The investigator or sub-investigators shall keep a record of all actions deviating from the trial 
protocol(s). The investigator or sub-investigators shall prepare a record describing the reason(s) etc. 
therefore, submit the record regarding to deviation in order to avoid imminent danger to the subject 
to the sponsor, and retain a copy. The investigator or sub-investigators may undertake deviations 
from or modification of the trial protocol(s) within prior written agreement between the investigator 
and the sponsor and written approval based on prior inspection by the IEC in medically unavoidable 
situation, in order to avoid imminent danger to the subject, In such an event, the investigator notify 
as soon as possible the sponsor, as well as the director of the institution and, via the director of the 
institution, to the IEC, of the nature of and reasons for the deviation or modification, together with a 
proposal for revision of the trial protocol(s), if appropriate, and obtain their approval, and at the 
same time shall obtain in writing the approval of the director of the institution and, via the director 
of institution, the agreement of the sponsor. 

Protocol No.: CTB258-P001 
29/33 
 
29 
 
 
Recording and Reporting the CRF 
The Investigator or sub-investigators shall prepare CRFs in accordance with the trial protocol(s), 
affix thereto his or her signature or personal seal, and submit them to the sponsor. The investigator 
shall retain copies of the CRFs submitted. 
The investigator shall inspect CRFs prepared by sub-investigators prior to their submission to 
the sponsor, and upon confirming that there is no problem, affix thereto his or her signature or 
personal seal.  The investigator shall also inspect modifications or revisions to CRFs undertaken 
by sub-investigators, and confirm that there is no problem. 
The investigator shall ensure that the data in the CRFs and all other documents submitted to the 
sponsor are accurate, complete, legible, and submitted in a timely manner, and that a subject 
identification code is used for identifying subjects. 
Data in the CRFs that are based on original materials shall not conflict with the original 
materials. When there is any discrepancy with the original, the investigator shall prepare a record 
explaining the reason therefore, submit it to the sponsor, and retain a copy. 
In modifying or correcting CRFs, the investigator or sub-investigators shall follow the manual 
provided by the sponsor. If there is any modification or correction whatever in a CRF, it must be 
dated and the signature or personal seal affixed. An explanation of the change must be provided if 
the change is critical.  Further the modification or correcting shall not be such as to render the 
initial writing unclear (i.e., an audit trail shall be maintained). 
The investigator should submit records of modification and correction of the case report form to 
the Sponsor and retain a photocopy of each record. 
 
Reports, etc. in the Course of the Trial 
In order to be available for ongoing review by the IEC, the investigator shall submit a written 
overview of the status of the trial to the director of the institution annually, or more frequently when 
requested by the IEC. 
With respect to any trial modification that could have a significant effect on the conduct of the 
trial or could increase the risk to subjects, the investigator shall promptly submit a written report to 
the sponsor, the director of the institution and, via the director of the institution, to the IEC.  
Except in cases in which the trial protocol(s), etc. provide that urgent notification is not required, 
the investigator shall notify the sponsor promptly of all serious adverse events. After the urgent 
notification, a detailed written report shall be made in due course. 
With respect to adverse events that are specified in the trial protocol(s) as serious for evaluation 
the safety of the investigational product(s), the investigator shall report to the sponsor, observing the 
reporting requirements and deadlines set forth in the trial protocol(s). 
The investigator shall report all serious adverse events to the director of the institution promptly 
and in writing. In this case, the investigator shall identify those of the reported serious adverse 
events involving serious and unpredictable adverse device effects. 

Protocol No.: CTB258-P001 
30/33 
 
30 
 
With respect to serious adverse events or serious adverse device effects, including cases of death, 
shall submit to the sponsor, director of the institution or IEC any additional information (autopsy 
reports, final treatment records or other requisite information that they may request). 
 
Termination or Suspension of the Trial 
When for any reason the trial is terminated or suspended, the investigator shall notify the subjects 
promptly to that effect, and shall ensure that subjects receive appropriate medical treatment and 
post-treatment. When the investigator terminates or suspends the trial, the investigator shall notify 
the director of the institution promptly and in writing to that effect, and shall provide a detailed 
written explanation for the termination or suspension. 
 
Completion of the Trial 
When the trial is completed, the investigator shall notify the director of the institution in writing to 
that effect, and report in writing an overview of the trial results. 
 
Storage of records 
The investigator shall retain essential documentation relating to the conduct of the trial in 
accordance with the directives of the director of the institution. 
 
20 INFORMED CONSENT 
Time to obtain consent 
The investigator or sub-investigator will obtain written consent by the trial subject prior to the 
commencement of the study. 
 
Methods for explaining to trial subjects 
The investigator (or sub-investigator) will give explanations to trial subjects.  Study collaborators 
can give supplemental explanations. 
The explanations should be given based on the explanation/consent document using terms which 
are the most easy to understand (non-technical terms). Questions made by trial subjects should be 
answered appropriately in the way the trial subjects can understand. 
 
Methods for obtaining consent 
(1) The investigator (or sub-investigator) who has given explanations will sign and date the 
consent document. 
(2) If any study collaborator has given supplemental explanations, the study collaborator will also 
sign and date the consent document. (Study collaborators are not allowed to solely give all 
necessary explanations to trial subjects.) 
(3) Supply the trial subject with the consent document and explanation document describing 

Protocol No.: CTB258-P001 
31/33 
 
31 
 
aforementioned necessary information and take sufficient time for the trial subject to decide 
whether or not he/she should participate in the clinical study. 
(4) Before obtaining consent, take sufficient time for the trial subject to sufficiently review the 
consent items and ask any questions. Answer the questions in a convincing manner. 
(5) Obtain the trial subject's spontaneous written consent to participate in the clinical study. 
(6) After obtaining the consent document signed and dated by the trial subject, the investigator (or 
sub-investigator) will enter the date of consent in the CRF and in the medical record. All 
consent documents must be retained. 
(7) Supply the trial subject with the copy (duplicate for the trial subject) of the consent document 
and the explanation document before the trial subject participates in the clinical study. 
(8) If the explanation document or consent document is subject to revision during the participation 
of the trial subject, follow the above procedures and re-obtain consent. 
 
Items Mentioned for the Written Informed Consent Form and Explanatory Documents 
(1)   The fact that the clinical study involves research. 
(2)   The purpose of the trial. 
(3)   The name and title of the investigator or sub-investigator, and how he or she can be 
contacted. 
(4)   The trial method (including the aspects of the trial that are experimental, subject’s 
inclusion/exclusion criteria, and when the trial is randomized, the probability of 
randomization for each treatment). 
(5)   The expected clinical benefits, and the foreseeable risks or inconveniences to the subjects. (If 
any benefits for the subject will not be expected, it must be informed to the subject.) 
(6)   When the persons to be enrolled as trial subjects are patients, the availability of other medical 
treatments for their condition, and the potential major benefits and risks of such treatments as 
are available. 
(7)   The expected duration of the subjects’ participation in the trial. 
(8)   That participation in the trial is voluntary; that the trial subject can refuse to participate in the 
trial or can withdraw from the trial at any time and that the subjects will not be 
disadvantaged or lose any benefit to which they are entitled if they refuse to enroll in the trial 
or if they withdraw from the trial after enrolling. 
(9)   Handling of investigational products in case of withdrawing from the clinical study. 
(10)  That the trial monitor, auditor, IEC, and regulatory authorities are allowed to examine the 
source data; that the confidentiality of the trial subjects will be protected when those data are 
examined by those persons; and that the subjects authorize the perusal of those data by those 
persons by sealing and/or signing the written consent form. 
(11)  That the subjects’ confidentiality will be protected even when the results of the clinical study   
      are published. 
(12)  The person in the study site whom the subjects should contact for further information about 

Protocol No.: CTB258-P001 
32/33 
 
32 
 
the trial or their rights, or if they develop a health problem associated with the trial. 
(13)  The compensation and medical treatment the trial subjects can receive should they develop a 
health problem associated with the trial. 
(14)  The number of subjects expected to be enrolled in the trial (including discrete variable). 
(15)  That if information is received that may affect the will of the subjects regarding the subjects’ 
ongoing participation in the trial, that information will be passed on promptly to the subjects. 
(16)  The circumstances under which or the reasons subjects will be withdrawn from the trial. 
(17)  The specifics about any expense the trial subjects will have to pay. 
(18)  The specifics about any cash or the like that will be paid to the trial subjects (including the 
arrangement for calculating the sum to be paid). 
(19)  Responsibilities of the trial subjects. 
(20)  Information about Institutional review board. 
(21)  The name of the study and the fact that the head of medical institute approved the conduct of  
      the study 
(22)  The procedure of disclosure of information 
(23)  The fact that the documents related to protocol and procedure of the study are available, as 
far as there is no interruption regarding protection of personal information and originality of 
the study, depending on the request from subject etc.. Also procedure of its access.  
(24)  Handling of personal information (including the procedure of anonymity, if applicable) 
(25)  The procedure of storing and disposal of the information 
(26)  Conflict of Interest of the investigator, medical institution etc. regarding the study, including 
funding source, personal income and so on. 
(27)  If there is a possibility that the sample or information of subjects might be used in future 
study or provided to other research institution, the fact and assumed contents when informed 
consent is obtained. 
 
Revision of Informed Consent Form and Explanatory Documents 
If the investigator acknowledges the necessity of revising the explanatory document used for 
obtaining consent, in the case of the obtainment of the information which may affect the trial 
subject's intention to continuously participate in the clinical study or in other cases, immediately 
revise the explanatory document and have the revision approved by the IEC. 
 
 
21 CONFLICT OF INTEREST 
Alcon Japan Ltd. is sponsor of this clinical study. Alcon Japan Ltd. and head of the medical 
institution will sign a contract for the clinical study. Financial cost of the study will be sponsored by 
Alcon Japan Ltd in accordance with the contract. 
Financial information to medical institutions paid by Alcon Japan Ltd. is disclosed at Homepage of 
Alcon Japan Ltd.

 
33 
 
Signature Page 
   The Sponsor and the Principal Investigator agree to conduct the study in 
accordance with the details and procedures described in this study protocol. 
The Sponsor and the Principal Investigator agree to conduct the study in accordance 
with the details and procedures described in this study protocol. 
       
Principal Investigator 
 
    Medical Institution :［                                  ］ 
 
    Affiliation and position : ［                              ］ 
 
         Name (Signature) : ［                                      ］ 
                                                                   (Signature) 
  
         Date :                        
 
 
 
     Sponsor 
 
      
      Director, Clinical Development, Alcon Japan, Ltd.   
 
         Name (Signature) : ［                                      ］ 
                                                                   (Signature) 
  
         Date :                        
 

 
 
 
 
 
 
 
 
Clinical Evaluation of FLACS (Femtosecond Laser Assisted 
Cataract Surgery) with Combination of LenSx and Centurion 
 
 
 
 
 
Clinical Study Protocol Supplemental Attachment 
 
 
 
 
A 
Clinical Study System, Participating Facilities and Principal Investigators 
B 
LenSx® Package Insert 
C 
Selection of Surgeon 
D 
Emery-Little Classification 
 
 
 
 
 
 
 
Alcon Japan Ltd. 
1-23-1 Toranomon, Minato-ku, Tokyo 
 
 
Protocol No.：CTB258-P001 
Version No.2：May 18 2018 
 

 
Appendix A Clinical Study System, Participating Facilities and 
Principal Investigators 
 
1. Clinical Study System 
1.1 
Sponsor 
Alcon Japan Ltd. 
 
 
 
 
 
1.2 
Study Supervisor 
    
 
 
1.3 
Clinical Development Director 
 
 
1.4 
Study Manager 
 
 
1.5 
Persons in Charge of Monitoring (delegate) 
. 
 
1.6 
Statistical Analysis Manager 
 
 
1.7 
Data Management Manager 
 
 
1.8 
Input of Study Data and Data Analysis 
 
 
1.9 
Input of Study Data and Data Analysis 
 
 
 

 
1.10 Sponsor Medical Expert 
 
 
 
 
2. Medical Institutions and Investigators 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 

 
Appendix C Selection of Surgeon 
 
Regarding combination of LenSx and Centurion (hereafter called LenSx group) and conventional cataract 
surgery (hereafter called Conventional group), the surgeons of this study surgery will be decided as 
follows. 
Surgeon A and Surgeon B should be the same person respectively for all surgery of this study. 
 
Group 
Surgical Procedure 
Surgeon 
LenSx 
Anterior capsulotomy and lens fragmentation by LenSx 
Surgeon A 
Surgical procedure after the above mentioned procedure 
Surgeon B 
Conventional All of the surgical procedure 
Surgeon B 
 
 
 

 
 Appendix D Emery-Little Classification 
 
The lens condition will be graded according to the following Emery-Little classification. More 
than two people different from the surgeon will classify the lens condition of each patients. 
 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 
Transparent or 
milky white 
White 
Yellow 
Amber 
Brown or black 
 
 
 
 
 
 
Reference：大鹿哲郎 編集『眼手術学 5. 白内障』 P.15, 株式会社 文光堂, 2012